Your SlideShare is downloading. ×
Update on New CSR Realignments Basic Oncology and Bioengineering
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Update on New CSR Realignments Basic Oncology and Bioengineering

410
views

Published on


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
410
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. PEER REVIEW ADVISORY COMMITTEE Update on New CSR Realignments Basic Oncology and Bioengineering Don Schneider National Institutes of Health U.S. Department of Health and Human Services February 1, 2010
  • 2. Continuous evolution/alignment of study sections is necessary
    • Science changes
    • CSR is committed to assessment
    • Study section size matters –
    • too small/too large
    • [Fewer than 50 applications
    • Is a problem]
  • 3. Three goals to consider
    • Look at recent reorganizations
    • Examine proposed guideline adjustments for Oncology 1 – Basic Translational (OBT) IRG
    • Re-examine Microscopic Imaging study section
  • 4. Cell Biology merged study sections
    • 2009/05 2010/05
    • Cell Structure Nuclear & Cytoplasmic
    • & Function 41 Struct, Functn, & Dynam
    • Nuclear Dynam 67
    • & Transport 45
    • Cellular Signaling Cellular Signaling
    • & Regulatory & Regulatory
    • Systems 58 Systems 84
    • Subtotal 144 151 applctns
  • 5. Digestv, Kidney, & Urologcl Sys merged study sections
    • 2009/05 2010/05
    • Gastrointestinal
    • Cell & Molecular
    • Biology 41
    • Gastrointestinal Gastrointestinal
    • Mucosal Mucosal
    • Pathobiology 53 Pathobiology 56
    • Hepatobiliary Hepatobiliary
    • Pathophysiology 64 Pathophysiology 78
    • Clinical & Clinical,
    • Integrative Integrative
    • Gastrointestinal & Molecular
    • Pathobiology 46 Gastroenterology 68
    • Subtotal 204 202
  • 6. Bioengineering merged panels
    • 2009/05 2010/05
    • Biodata Management Biodata Management
    • & Analysis 40 & Analysis 88
    • SEP 28
    • Modeling & Analysis Modeling & Analysis
    • Of Biological Of Biological
    • Systems 39 Systems 72
    • Microscopic Microscopic
    • Imaging 20 Imaging 27
    • Subtotal 127 187
  • 7. Interim analysis of realignments is positive
    • Workloads improve (except Micros Imaging)
    • Science and fairness of review are probably better
    • CSR needs metric/tool to measure scientific impact
  • 8. CSR formed five review divisions, January 2009 Translational and Clinical Sciences Cardiovascular and Respiratory Sciences Surgical Sciences, Biomedical Imaging and Bioengineering Musculoskeletal, Oral & Skin Sciences Oncology: Translational Clinical Vascular and Hematology Physiological and Pathological Sciences Endocrinology, Metabolism, Nutrition & Reproductive Sciences Immunology Infectious Diseases & Microbiology Digestive, Kidney & Urological Systems Neuroscience, Development and Aging Brain Disorders & Clinical Neuroscience Molecular, Cellular & Developmental Neuroscience Integrative, Functional & Cognitive Neuroscience Emerging Technologies & Training in Neuroscience Biology of Development & Aging Biobehavioral & Behavioral Processes Risk, Prevention& Health Behavior Population Sciences & Epidemiology Healthcare Delivery & Methodologies AIDS & AIDS Related Research AIDS, Behavioral and Population Sciences Basic and Integrative Biological Sciences Biological Chemistry & Macromolecular Biophysics Bioengineering Sciences & Technologies Genes, Genomes & Genetics Oncology: Basic Translational Cell Biology Interdisciplinary Molecular Sciences & Training
  • 9. Oncology 1 – Basic & Translational IRG was established and reviewed
    • Split ONC to form OBT & OTC January 2009
    • Collected feedback from reviewers two cycles  (October and February meetings)
    • Discussed feedback with Chairs (Chief and DD)
    • Reviewed by CSR Director et al September 23, 2009
    • [Chief – Cathleen Cooper]
  • 10. Realignments are proposed for OBT study sections
    • For emerging trends, clarity of scientific scope, and workload balance, guideline adjustments are proposed:
    • Cancer Molecular Pathology study section (CAMP) –about 110 applications a cycle; focuses on oncogenes and tumor suppressors; move telomeres and epigenomics
    • Cancer Genetics study section (CG) – about 75 applications a cycle; focuses on chromosomal integrity and stability; add telomeres and epigenomics (would fit well)
    • Cancer Etiology study section (CE) – about 90 applications a cycle; focuses on DNA repair and environmental carcinogenesis; move epigenomics unless focus is environmental
    • Estimated result: about 95, 90, and 90 applications
  • 11. Bioengineering Sciences and Technologies IRG was formed in 2004
    • Regular Study Sections
    • Biodata Management and Analysis (BDMA)
    • Biomaterials and Biointerfaces (BMBI)
    • Gene and Drug Delivery Systems (GDD)
    • Instrumentation Systems and Development (ISD)
    • Modeling and Analysis of Biological Systems (MABS)
    • Microscopic Imaging (MI)
    • Nanotechnology (NANO)
    • [Chief – George Chacko]
  • 12. Steps to realign were taken a year ago
    • Original study sections were hybrids in that R01s and R43s were reviewed together – no longer possible
    • BDMA & MI were small, about 50 applications each
    • Via Working Group and PRAC, BDMA was combined with a software SEP and scope of MI was expanded
  • 13. 2009 Realignment worked for BDMA, not for MI
  • 14. Microscopic Imaging and Spectroscopy
    • The study section focuses on review of applications on techniques and instrumentation for microscopic visualization of molecules, organelles, and model systems
    • Development and improvement of microscopic imaging and spectroscopy
    • Development of imaging tools/software
    • Image acquisition and analysis, including single particle
  • 15. Instrumentation Systems and Development shares interests with Microscopic Imaging
    • Optical and spectroscopic instrumentation
    • Microfabrication
    • Automation and integration
    • Sensing of single cells
  • 16. MIS, ISD, & EBT share interests
    • Microscopic Imaging and Spectroscopy, in BST, focus is to develop techniques to visualize molecules, organelles, and cells
    • Instrumentation and Systems Development, in BST, focus is to develop instrumentation for biological research
    • Enabling Bioanalytical and Biophysical Technologies, in BCMB, focus is development of bioanalytical tools to probe molecules
  • 17. Options presented to Working Group
    • [Working within the Bioengineering IRG]
    • Terminate MIS
    • Merge MIS with ISD
    • Expand the scope of MIS
  • 18. Bioengineering Working Group #2 met January 2010
    • ROSTER
    • Wah Chiu, PhD (Baylor College of Medicine)
    • Robert M Dickson, PhD (Georgia Institute of Technology)
    • Michael Gilson, MD, PhD (University of Maryland)
    • Enrico Gratton, PhD (University of California Irvine)
    • Jerome Mertz, PhD (Boston University)
    • Stephen C Miller, PhD (University of Massachusetts Worcester)
    • Amy Palmer, PhD (University of Colorado Boulder)
    • Peter Sorger, PhD (Massachusetts Institute of Technology)
    • Shankar Subramaniam, PhD (University of California San Diego)
    • Stephen Wong, PhD (Cornell University Weill)
    • Xiaowei Zhuang, PhD (Harvard University)
    • NIH: James Deatherage, PhD (NIGMS); Catherine Lewis, PhD (NIGMS); George Chacko, PhD (CSR); Don Schneider, PhD (CSR)
  • 19. Working Group Expressed Preferences
    • Terminate Microscopic Imaging - WG least enthusiasm, integrated basic imaging panel has value, will grow
    • Merge MIS, principally with Instrumentation and Systems Development - WG medium enthusiasm
    • Expand scope and continue Microscopic Imaging - WG considerable enthusiasm
  • 20. Should MI be continued?
    • Element of “Been there, done that”
    • Related issues
    • - EBT study section
    • - IMST IRG
  • 21. CSR created Interdisciplinary Molecular Sciences & Training IRG January 2009
    • IMST uses SEPs to review all fellowship and small business applications for Basic & Integrative Biological Sciences (basic oncology, bio-chemistry/biophysics, bioengineering, cell biology, and genetics)
    • IMST uses SEPs to review interdisciplinary special applications, e.g., some P01s, P41s, and S10s
    • IMST was recently chartered, with understanding that it would form a regular, chartered study section
    • [Chief – Ross Shonat]
  • 22. Taking a bolder, broader view
    • EBT averages about 60 applications a round
    • MI averages about 25 applications a round
    • EBT and MI have complementary interests
    • IMST IRG needs a chartered study section
    • 25 + 60 = 85, close to ideal
    • Create EBIT, Enabling Bioanalytical and Imaging Technologies
  • 23. PRAC input sought
    • Oncology 1 – Basic Translational IRG (OBT)
    • Move telomeres and epigenomics from Cancer Molecular Pathology to Cancer Genetics
    • Move some epigenomics from Cancer Etiology to Cancer Genetics
    • Microscopic Imaging and Spectroscopy
    • Allow more time for growth, OR
    • Merge with Enabling Bioanalytical and Biophysical Technologies and move to Interdisciplinary Molecular Sciences and Training IRG
  • 24.
    • Discussion